Programming the Immune System to Produce Drugs

Posted on by immusoft

MPS I is a rare genetic disease that is incurable and lethal by age 12. Seattle-based Immusoft thinks it can harness a key part of the immune system to manufacture a missing enzyme needed to treat the disease. It represents a broader effort on the part of the company to develop a platform to treat a wide range of disease by turning immune system cells into drug factories.